Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 Jul;96(1):217–223. doi: 10.1172/JCI118023

Deficient antigen-presenting cell function in multiple genetic complementation groups of type II bare lymphocyte syndrome.

S Kovats 1, G T Nepom 1, M Coleman 1, B Nepom 1, W W Kwok 1, J S Blum 1
PMCID: PMC185191  PMID: 7615790

Abstract

The absence of HLA class II gene expression in type II bare lymphocyte syndrome (BLS) results from defective transcriptional activation of class II histocompatibility genes. Genetic studies have revealed that distinct defects in multiple trans-acting factors result in the immunodeficient BLS phenotype. We studied antigen-presenting cell (APC) function in DR-transfected BLS cells derived from multiple complementation groups. Each BLS cell line displayed the same defective APC phenotype: an inability to mediate class II-restricted presentation of exogenous protein antigens, and structurally altered class II alpha beta dimers. Expression of the HLA class II-like genes DMA and DMB, previously implicated in antigen presentation, was reduced or absent in the BLS cells. Fusion of BLS cells with cell line 721.174, which has a genomic deletion of HLA class II genes, coordinately restores class II structural gene and DM gene expression and a wild-type APC phenotype. Thus each of the molecular defects that silences class II structural gene transcription also results in a defective APC phenotype, providing strong evidence for coregulation of these two functionally linked pathways.

Full text

PDF
217

Images in this article

219Image
on p.219
220Image
on p.220

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avva R. R., Cresswell P. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity. 1994 Dec;1(9):763–774. doi: 10.1016/s1074-7613(94)80018-9. [DOI] [PubMed] [Google Scholar]
  2. Brooks A. G., Campbell P. L., Reynolds P., Gautam A. M., McCluskey J. Antigen presentation and assembly by mouse I-Ak class II molecules in human APC containing deleted or mutated HLA DM genes. J Immunol. 1994 Dec 15;153(12):5382–5392. [PubMed] [Google Scholar]
  3. Bull M., van Hoef A., Gorski J. Transcription analysis of class II human leukocyte antigen genes from normal and immunodeficient B lymphocytes, using polymerase chain reaction. Mol Cell Biol. 1990 Jul;10(7):3792–3796. doi: 10.1128/mcb.10.7.3792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bénichou B., Strominger J. L. Class II-antigen-negative patient and mutant B-cell lines represent at least three, and probably four, distinct genetic defects defined by complementation analysis. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4285–4288. doi: 10.1073/pnas.88.10.4285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ceman S., Rudersdorf R., Long E. O., Demars R. MHC class II deletion mutant expresses normal levels of transgene encoded class II molecules that have abnormal conformation and impaired antigen presentation ability. J Immunol. 1992 Aug 1;149(3):754–761. [PubMed] [Google Scholar]
  6. Chang C. H., Flavell R. A. Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med. 1995 Feb 1;181(2):765–767. doi: 10.1084/jem.181.2.765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chin K. C., Mao C., Skinner C., Riley J. L., Wright K. L., Moreno C. S., Stark G. R., Boss J. M., Ting J. P. Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction. Immunity. 1994 Nov;1(8):687–697. doi: 10.1016/1074-7613(94)90039-6. [DOI] [PubMed] [Google Scholar]
  8. Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol. 1994;12:259–293. doi: 10.1146/annurev.iy.12.040194.001355. [DOI] [PubMed] [Google Scholar]
  9. DeMars R., Chang C. C., Shaw S., Reitnauer P. J., Sondel P. M. Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. Hum Immunol. 1984 Oct;11(2):77–97. doi: 10.1016/0198-8859(84)90047-8. [DOI] [PubMed] [Google Scholar]
  10. Doyle C., Ford P. J., Ponath P. D., Spies T., Strominger J. L. Regulation of the class II-associated invariant chain gene in normal and mutant B lymphocytes. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4590–4594. doi: 10.1073/pnas.87.12.4590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Durand B., Kobr M., Reith W., Mach B. Functional complementation of major histocompatibility complex class II regulatory mutants by the purified X-box-binding protein RFX. Mol Cell Biol. 1994 Oct;14(10):6839–6847. doi: 10.1128/mcb.14.10.6839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fling S. P., Arp B., Pious D. HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature. 1994 Apr 7;368(6471):554–558. doi: 10.1038/368554a0. [DOI] [PubMed] [Google Scholar]
  13. Gladstone P., Pious D. Identification of a trans-acting function regulation HLA-DR expression in a DR-negative B cell variant. Somatic Cell Genet. 1980 Mar;6(2):285–298. doi: 10.1007/BF01538802. [DOI] [PubMed] [Google Scholar]
  14. Hume C. R., Lee J. S. Congenital immunodeficiencies associated with absence of HLA class II antigens on lymphocytes result from distinct mutations in trans-acting factors. Hum Immunol. 1989 Dec;26(4):288–309. doi: 10.1016/0198-8859(89)90007-4. [DOI] [PubMed] [Google Scholar]
  15. Hume C. R., Shookster L. A., Collins N., O'Reilly R., Lee J. S. Bare lymphocyte syndrome: altered HLA class II expression in B cell lines derived from two patients. Hum Immunol. 1989 May;25(1):1–11. doi: 10.1016/0198-8859(89)90065-7. [DOI] [PubMed] [Google Scholar]
  16. Johnson J. P., Meo T., Riethmüller G., Schendel D. J., Wank R. Direct demonstration of an HLA-DR allotypic determinant on the low molecular weight (beta) subunit using a mouse monoclonal antibody specific for DR3. J Exp Med. 1982 Jul 1;156(1):104–111. doi: 10.1084/jem.156.1.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kappler J. W., Skidmore B., White J., Marrack P. Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition. J Exp Med. 1981 May 1;153(5):1198–1214. doi: 10.1084/jem.153.5.1198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kelly A. P., Monaco J. J., Cho S. G., Trowsdale J. A new human HLA class II-related locus, DM. Nature. 1991 Oct 10;353(6344):571–573. doi: 10.1038/353571a0. [DOI] [PubMed] [Google Scholar]
  19. Klein C., Lisowska-Grospierre B., LeDeist F., Fischer A., Griscelli C. Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome. J Pediatr. 1993 Dec;123(6):921–928. doi: 10.1016/s0022-3476(05)80388-9. [DOI] [PubMed] [Google Scholar]
  20. Kovats S., Drover S., Marshall W. H., Freed D., Whiteley P. E., Nepom G. T., Blum J. S. Coordinate defects in human histocompatibility leukocyte antigen class II expression and antigen presentation in bare lymphocyte syndrome. J Exp Med. 1994 Jun 1;179(6):2017–2022. doi: 10.1084/jem.179.6.2017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kwok W. W., Schwarz D., Nepom B. S., Hock R. A., Thurtle P. S., Nepom G. T. HLA-DQ molecules form alpha-beta heterodimers of mixed allotype. J Immunol. 1988 Nov 1;141(9):3123–3127. [PubMed] [Google Scholar]
  22. Lampson L. A., Levy R. Two populations of Ia-like molecules on a human B cell line. J Immunol. 1980 Jul;125(1):293–299. [PubMed] [Google Scholar]
  23. Lisowska-Grospierre B., Charron D. J., de Préval C., Durandy A., Griscelli C., Mach B. A defect in the regulation of major histocompatibility complex class II gene expression in human HLA-DR negative lymphocytes from patients with combined immunodeficiency syndrome. J Clin Invest. 1985 Jul;76(1):381–385. doi: 10.1172/JCI111974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mao C., Davies D., Kerr I. M., Stark G. R. Mutant human cells defective in induction of major histocompatibility complex class II genes by interferon gamma. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2880–2884. doi: 10.1073/pnas.90.7.2880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mellins E., Kempin S., Smith L., Monji T., Pious D. A gene required for class II-restricted antigen presentation maps to the major histocompatibility complex. J Exp Med. 1991 Dec 1;174(6):1607–1615. doi: 10.1084/jem.174.6.1607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Mellins E., Smith L., Arp B., Cotner T., Celis E., Pious D. Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature. 1990 Jan 4;343(6253):71–74. doi: 10.1038/343071a0. [DOI] [PubMed] [Google Scholar]
  27. Morris P., Shaman J., Attaya M., Amaya M., Goodman S., Bergman C., Monaco J. J., Mellins E. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature. 1994 Apr 7;368(6471):551–554. doi: 10.1038/368551a0. [DOI] [PubMed] [Google Scholar]
  28. Nocera A., Barocci S., De Palma R., Gorski J. Analysis of transcripts of genes located within the HLA-D region in B cells from an HLA-severe combined immunodeficiency individual. Hum Immunol. 1993 Nov;38(3):231–234. doi: 10.1016/0198-8859(93)90547-e. [DOI] [PubMed] [Google Scholar]
  29. Radka S. F., Machamer C. E., Cresswell P. Analysis of monoclonal antibodies reactive with human class II beta chains by two-dimensional electrophoresis and Western blotting. Hum Immunol. 1984 Jul;10(3):177–186. doi: 10.1016/0198-8859(84)90038-7. [DOI] [PubMed] [Google Scholar]
  30. Radka S. F., Machamer C., Cresswell P., Kostyu D. D., Ward F. E., Amos D. B. SFR3-DR5, a monoclonal antibody with HLA-DR5 specificity. J Immunol. 1983 Apr;130(4):1863–1866. [PubMed] [Google Scholar]
  31. Riberdy J. M., Cresswell P. The antigen-processing mutant T2 suggests a role for MHC-linked genes in class II antigen presentation. J Immunol. 1992 Apr 15;148(8):2586–2590. [PubMed] [Google Scholar]
  32. Riberdy J. M., Newcomb J. R., Surman M. J., Barbosa J. A., Cresswell P. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature. 1992 Dec 3;360(6403):474–477. doi: 10.1038/360474a0. [DOI] [PubMed] [Google Scholar]
  33. Salter R. D., Howell D. N., Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics. 1985;21(3):235–246. doi: 10.1007/BF00375376. [DOI] [PubMed] [Google Scholar]
  34. Seidl C., Saraiya C., Osterweil Z., Fu Y. P., Lee J. S. Genetic complexity of regulatory mutants defective for HLA class II gene expression. J Immunol. 1992 Mar 1;148(5):1576–1584. [PubMed] [Google Scholar]
  35. Sette A., Ceman S., Kubo R. T., Sakaguchi K., Appella E., Hunt D. F., Davis T. A., Michel H., Shabanowitz J., Rudersdorf R. Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant. Science. 1992 Dec 11;258(5089):1801–1804. doi: 10.1126/science.1465617. [DOI] [PubMed] [Google Scholar]
  36. Stebbins C. C., Loss G. E., Jr, Elias C. G., Chervonsky A., Sant A. J. The requirement for DM in class II-restricted antigen presentation and SDS-stable dimer formation is allele and species dependent. J Exp Med. 1995 Jan 1;181(1):223–234. doi: 10.1084/jem.181.1.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Steimle V., Otten L. A., Zufferey M., Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell. 1993 Oct 8;75(1):135–146. [PubMed] [Google Scholar]
  38. Steimle V., Siegrist C. A., Mottet A., Lisowska-Grospierre B., Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science. 1994 Jul 1;265(5168):106–109. doi: 10.1126/science.8016643. [DOI] [PubMed] [Google Scholar]
  39. Stimac E., Urieli-Shoval S., Kempin S., Pious D. Defective HLA DRA X box binding in the class II transactive transcription factor mutant 6.1.6 and in cell lines from class II immunodeficient patients. J Immunol. 1991 Jun 15;146(12):4398–4405. [PubMed] [Google Scholar]
  40. Woods A., Chen H. Y., Trumbauer M. E., Sirotina A., Cummings R., Zaller D. M. Human major histocompatibility complex class II-restricted T cell responses in transgenic mice. J Exp Med. 1994 Jul 1;180(1):173–181. doi: 10.1084/jem.180.1.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Yang Z., Accolla R. S., Pious D., Zegers B. J., Strominger J. L. Two distinct genetic loci regulating class II gene expression are defective in human mutant and patient cell lines. EMBO J. 1988 Jul;7(7):1965–1972. doi: 10.1002/j.1460-2075.1988.tb03034.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Yu L. P., Sheehy M. J. The cryptic HLA-DQA2 ("DX alpha") gene is expressed in human B cell lines. J Immunol. 1991 Dec 15;147(12):4393–4397. [PubMed] [Google Scholar]
  43. de Préval C., Lisowska-Grospierre B., Loche M., Griscelli C., Mach B. A trans-acting class II regulatory gene unlinked to the MHC controls expression of HLA class II genes. Nature. 1985 Nov 21;318(6043):291–293. doi: 10.1038/318291a0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES